Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Dyne Therapeutics, Inc.”

49 pharma patents match "Dyne Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 49
Index total 30,257
Page 1 / 3

Quick answer

This filtered view shows 49 pharmaceutical patents matching "Dyne Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

49 results for “Dyne Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12428487

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  2. US 12403203

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  3. US 12397062

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  4. US 12370264

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  5. US 12357703

    Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping

    Dyne Therapeutics, Inc. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  6. US 12329824

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  7. US 12329825

    Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject

    Dyne Therapeutics, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  8. US 12325753

    Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  9. US 12319743

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  10. US 12280122

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  11. US 12263225

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  12. US 12239717

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  13. US 12239716

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  14. US 12173079

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  15. US 12173078

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  16. US 12144868

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  17. US 12144867

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  18. US 12128109

    Muscle targeting complexes and formulations for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  19. US 12102687

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  20. US 12097263

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  21. US 12018087

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  22. US 12012460

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  23. US 12005124

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  24. US 11986537

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted May 21, 2024 · Expires May 16, 2044

    granted